Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: hyprolose; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified water; stearic acid; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: magnesium stearate; stearic acid; microcrystalline cellulose; lactose monohydrate; hyprolose; purified water; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet - excipient ingredients: hyprolose; microcrystalline cellulose; lactose monohydrate; stearic acid; purified water; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: hyprolose; magnesium stearate; purified water; stearic acid; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; purified water; titanium dioxide; iron oxide yellow; macrogol 4000 - apo-olmesartan is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; purified water; hyprolose; titanium dioxide; iron oxide yellow; macrogol 4000 - apo-olmesartan is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified water; hyprolose; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified water; microcrystalline cellulose; hyprolose; lactose monohydrate; titanium dioxide; iron oxide yellow; macrogol 4000 - olmesartan sandoz is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: hypromellose; microcrystalline cellulose; lactose monohydrate; hyprolose; purified water; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 4000 - olmesartan sandoz is indicated for the treatment of hypertension.

United States - English - NLM (National Library of Medicine)

doh central pharmacy - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as